Mission Statement, Vision, & Core Values of Alkermes plc (ALKS)

Are you curious about what drives a leading biopharmaceutical company focused on neuroscience? Let's delve into the core of Alkermes plc (ALKS), a company that reported total revenues of $1.56 billion for 2024 and a GAAP net income from continuing operations of $372 million, with earnings per share at $2.20. What are the guiding principles behind their innovative medicines and strategic decisions, especially with their impressive 18% increase in net sales of proprietary products?

Understanding a company's mission, vision, and core values provides insight into its culture, goals, and how it operates. How do these elements shape Alkermes' approach to addressing unmet needs in treating complex psychiatric and neurological disorders, and how do they contribute to their financial success, including the $58.4 million in royalties from sales of INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA, and INVEGA HAFYERA/BYANNLI in Q3 2024?

Alkermes plc (ALKS) An Overview of

Alkermes plc is a global biopharmaceutical company committed to developing innovative medicines for the treatment of central nervous system (CNS) diseases. Founded in 1987 and headquartered in Dublin, Ireland, Alkermes has a history of developing and commercializing pharmaceutical products that address unmet medical needs. As of April 2025, the company continues to focus on research and development in areas such as schizophrenia, depression, and other neurological disorders.

Alkermes' portfolio includes both proprietary products and partnered products. Key proprietary products include:

• ARISTADA (aripiprazole lauroxil): An extended-release injectable antipsychotic for the treatment of schizophrenia.
• VIVITROL (naltrexone for extended-release injectable suspension): A once-monthly injectable medication for the treatment of alcohol dependence and prevention of relapse to opioid dependence after detoxification.
• LYBALVI (olanzapine and samidorphan): An atypical antipsychotic for the treatment of adults with schizophrenia and for the treatment of bipolar I disorder.

In the 2024 fiscal year, Alkermes reported strong financial performance. The company highlighted record revenues, driven primarily by the performance of its key products. ARISTADA, in particular, has seen substantial growth, contributing significantly to the overall revenue increase. LYBALVI is another key product driving growth for Alkermes. The company's strategic focus on CNS disorders and its ability to develop and commercialize innovative treatments have been pivotal in achieving these financial results.

Alkermes' financial results for 2024 showcased a robust performance, indicating a strong position in the market. The company's revenue streams are diversified, with significant contributions from both proprietary and partnered products. This diversification helps to mitigate risk and ensures a stable financial foundation for future growth. Alkermes also continues to invest in research and development, signaling a commitment to innovation and the development of new treatments for CNS diseases.

Alkermes is a leading biopharmaceutical company focused on central nervous system (CNS) diseases. Want to understand why Alkermes is successful? Find out more here: Breaking Down Alkermes plc (ALKS) Financial Health: Key Insights for Investors

Alkermes plc (ALKS) Mission Statement

Alkermes plc is a global biopharmaceutical company committed to developing innovative medicines for the treatment of central nervous system (CNS) diseases, with a focus on neuroscience and oncology. Alkermes strives to improve outcomes for patients, families, and communities impacted by serious mental illness, addiction, and cancer [1].

The company applies its scientific expertise, proprietary technologies, and global resources to develop products designed to make a meaningful difference in how patients manage their diseases [16]. Alkermes focuses on conditions that have traditionally been overlooked or stigmatized [1].

Alkermes has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline addressing CNS disorders such as addiction, schizophrenia, and depression [17]. As of February 2025, Alkermes has approximately 1,800 employees worldwide [5].

The company's corporate headquarters are located in Ireland, with U.S. corporate offices and an R&D facility in Massachusetts, and a GMP manufacturing facility in Ohio [1, 5].

Alkermes' mission is also reflected in its corporate responsibility initiatives. The company strives to have a positive impact on its employees, communities, the environment, and society. Alkermes supports research, education, and patient advocacy programs [14].

For the fiscal year ending December 31, 2024, Alkermes reported its annual report on Form 10-K [7, 9]. In 2023, Alkermes generated $1.6 billion in revenue [15].

Alkermes' CEO, Richard Pops, stated that the company sees itself as having a responsibility and opportunity to contribute more broadly and serve as a positive example for others [5].

Related article: Exploring Alkermes plc (ALKS) Investor Profile: Who’s Buying and Why?

Alkermes plc (ALKS) Vision Statement

Alkermes plc, a biopharmaceutical company, focuses on developing innovative medicines for central nervous system (CNS) diseases. Understanding its vision, mission, and core values provides insight into its strategic objectives and operational priorities. As of April 2025, here's an overview based on the latest available information.

Mission Statement

Alkermes' mission is centered on developing and commercializing innovative medicines and changing the course of lives for people living with serious diseases. This involves:

• Research and Development: Focusing on novel drug candidates, particularly in the field of neuroscience.
• Clinical Trials: Conducting rigorous clinical trials to demonstrate the safety and efficacy of their drug candidates.
• Regulatory Approval: Pursuing regulatory approvals from agencies like the FDA to bring new treatments to market.
• Commercialization: Launching and marketing approved products to ensure they reach the patients who need them.

In 2024, Alkermes reported total revenues of $1.18 billion, reflecting the impact of their commercialized products and collaborations. Their R&D expenses were $481.1 million, underscoring their commitment to innovation.

Vision Statement

Alkermes envisions a future where serious diseases, particularly those affecting the central nervous system, can be effectively managed with innovative treatments. This vision includes:

• Leading in Neuroscience: Aiming to be a leader in developing treatments for CNS disorders.
• Improving Patient Outcomes: Striving to improve the lives of patients by providing them with better treatment options.
• Driving Innovation: Continuously seeking new scientific breakthroughs and developing novel drug candidates.
• Expanding Product Portfolio: Expanding their portfolio of approved products and pipeline of drug candidates.

As of the 2024 fiscal year, Alkermes had invested significantly in their pipeline, with key programs targeting schizophrenia, depression, and other CNS disorders. For instance, ALKS 2680, an orexin-2 receptor agonist, is in phase 1 clinical development for the treatment of narcolepsy. The company's annual report highlights these advancements, showcasing their dedication to pioneering new treatments.

Core Values

Alkermes' core values guide its operations and decision-making. These values typically include:

• Innovation: Encouraging a culture of innovation and creativity to drive scientific breakthroughs.
• Integrity: Maintaining the highest ethical standards in all aspects of their business.
• Collaboration: Fostering collaboration among employees, partners, and stakeholders.
• Patient Focus: Putting the needs of patients first and striving to improve their lives.
• Excellence: Pursuing excellence in all that they do, from research and development to commercialization.

In 2024, Alkermes emphasized its commitment to corporate responsibility, including environmental, social, and governance (ESG) initiatives. These efforts align with their core values and demonstrate their dedication to making a positive impact on society.

To delve deeper into Alkermes and its investors, check out this informative resource: Exploring Alkermes plc (ALKS) Investor Profile: Who’s Buying and Why?

Alkermes plc (ALKS) Core Values of

Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in the areas of neuroscience and oncology. The company has a research and development pipeline of new medicines and a portfolio of marketed products. Alkermes' commitment to its core values is evident in its approach to innovation, patient care, and ethical business practices. You can learn more about the company's history and mission in this article: Alkermes plc (ALKS): History, Ownership, Mission, How It Works & Makes Money.

Innovation

Alkermes places a high value on innovation, as evidenced by its significant investment in research and development. In 2024, Alkermes reported total research and development (R&D) expenses of $473.8 million. This investment fuels the discovery and development of new medicines aimed at addressing unmet needs in neuroscience and oncology. The company's pipeline includes several promising candidates, reflecting its dedication to advancing scientific knowledge and improving patient outcomes.

• A key aspect of Alkermes' innovation strategy is its focus on novel drug delivery technologies.
• Alkermes is also exploring new therapeutic modalities, such as RNA interference (RNAi) and gene therapy, to expand its capabilities and address a wider range of diseases.

The company's commitment to innovation extends beyond its internal R&D efforts. Alkermes actively collaborates with academic institutions, research organizations, and other biotechnology companies to leverage external expertise and accelerate the development of new medicines.

Patient Focus

Alkermes demonstrates a strong commitment to patients by prioritizing their needs and well-being in all aspects of its business. This patient-centric approach is evident in the company's efforts to develop medicines that improve patient outcomes and quality of life. Alkermes actively engages with patient advocacy groups to understand their perspectives and incorporate their feedback into its drug development programs. This collaboration ensures that the company's medicines are designed to address the specific needs and challenges faced by patients.

• Alkermes provides comprehensive patient support programs to help individuals access its medicines and manage their conditions effectively. These programs offer a range of services, including financial assistance, educational resources, and personalized support from healthcare professionals.
• Alkermes is committed to ensuring that its medicines are accessible to patients who need them. The company works with payers, healthcare providers, and patient advocacy groups to advocate for policies that promote access to innovative medicines.

Alkermes is dedicated to conducting clinical trials with the highest ethical standards and ensuring the safety and well-being of participants. The company adheres to rigorous protocols and guidelines to protect the rights and privacy of patients involved in its research studies.

Integrity

Alkermes upholds the highest standards of integrity in all its business dealings. The company is committed to ethical conduct, transparency, and accountability. Alkermes has implemented a comprehensive compliance program to ensure that its employees adhere to all applicable laws, regulations, and company policies. This program includes regular training, monitoring, and auditing to detect and prevent any potential violations.

• Alkermes is committed to transparency in its interactions with healthcare professionals, payers, and other stakeholders. The company discloses all financial relationships with healthcare providers and organizations to ensure that its activities are conducted in an ethical and unbiased manner.
• Alkermes has a strong commitment to corporate social responsibility. The company supports various charitable organizations and initiatives that promote health, education, and community development.

In 2024, Alkermes reported revenues of $1.18 billion, reflecting its success in developing and commercializing innovative medicines while maintaining the highest standards of integrity.